La fractures do not heal alone, even with time and require bone reconstruction surgery. At the European level, not less than one million patients each year, justify such treatment. It is therefore not surprising that the National Security Agency of Medicines and Health Products (MSNA), has agreed to launch an original clinical trial in orthopedic surgery. It should assess the effectiveness of "adult stem cells, combined with a biomaterial" to repair the bone. Explications.
Financé by the European Commission, the project (Reborne for regeneration of bone defects using new biomedical engineering approaches) is coordinated by INSERM. "Its originality lies in the fact that the use of mesenchymal stem cells (MSCs) present in the bone marrow of the patient. Amplified in culture, they are associated with a synthetic bone substitute. The whole is then grafted to the fracture to intervene in the healing, "says INSERM .
Ce bone substitute is used in some way as a scaffold. It allows the proliferation of stem cells. "These then divide into bone cells and regenerate bone at the fracture," says INSERM. Started 3 years ago, preclinical tests proved promising.
"The goal of the test is to demonstrate that the use of biomaterials and stem cells is safe and at least equivalent to standard treatments, without their disadvantages," insists Pierre Layrolle, Research Director INSERM and coordinator of the project Reborne. "This surgery is less invasive and preserves the patient's bone stock" .
L'ANSM agreed Jan. 3, 2013, for the test begins now in France. Seven patients followed at the University Hospital of Créteil and University Hospital of Tours. At the end of the project to the end of 2014, a total of 30 patients (...) Read more about destinationsante.comEpidémies winter: flu "atypical" Gastro: the epidemic weakens pasMenus health: land and sea, the best two mondesRecevez newsletter Destination SantéAccédez the Destination section Femme
هیچ نظری موجود نیست:
ارسال یک نظر